Resources

Resources

Investor FAQs
Show All
Where are UroGen Pharma’s corporate headquarters?
UroGen is headquartered in Princeton, NJ with operations in Israel.
When was UroGen Pharma founded?
UroGen Pharma was founded in 2004.
Who are the members of UroGen Pharma's Leadership Team?
You can view our Leadership Team by visiting the Leadership Team section on our website.
Who are the members of UroGen Pharma's Executive Leadership?
You can view our Leadership Team by visiting the Leadership team section on our website.
On which exchange is UroGen Pharma listed and what is the ticker symbol?
UroGen is traded on the NASDAQ Global Market under the symbol “URGN.”
Who is UroGen Pharma's independent registered public accounting firm?
UroGen Pharma’s independent registered public accounting firm is PriceWaterhouseCoopers Israel.

PriceWaterhouseCoopers Israel
PO Box 50005
Tel-Aviv 6150001
Israel
Telephone: [972] (0) 3 795 4555
When is UroGen Pharma’s fiscal year end?
UroGen Pharma’s fiscal year end is December 31.
When did UroGen Pharma go public?
UroGen Pharma went public on May 4, 2017.
How can I obtain UroGen Pharma’s investor relations materials?
You can obtain UroGen Pharma's investor materials in the Investors section of our website. Navigate to the materials of your choice using the menu in the upper left side of this page.
How can I purchase shares?
Shares can be purchased through a stockbroker of your choice.
Does UroGen Pharma have a direct stock purchase plan?
UroGen Pharma does not offer a direct stock purchase plan at this time.
Does UroGen Pharma pay dividends and have a dividend reinvestment program?
Currently, UroGen Pharma does not pay dividend or offer a dividend reinvestment program.
Who is UroGen Pharma’s transfer agent and how do I contact them?

UroGen Pharma’s transfer agent is Computershare Information. Please see below for the transfer agent contact information.

Written requests
By regular mail:
Computershare
PO Box 505000
Louisville KY 40233-5000

By overnight delivery:
Computershare
462 South 4th Street, Suite 1600
Louisville KY 40202

How can I get a copy of your Annual Report or any other Investor materials (i.e., Investor Relations kit, 10-k)?
Quarterly & Annual Reports and other investor materials are available under the SEC Filings page of the Investors section of the corporate website. Additionally, all SEC filings can also be accessed directly from the SEC website.
Where can I find recent UroGen Pharma press releases?
You can view our recent press releases by visiting the Press Releases section of our website.
Who can I contact if I am a member of the media?
Eric Van Zanten, Head of Communications, at 464-844-6084 (Office), 610-529-6219 (Mobile), or eric.vanzanten@urogen.com.
Where can I find more information on UroGen Pharma’s R&D programs?
You can view UroGen Pharma’s R&D plans by visiting the Pipeline & Partners section of our website.
How can I sign up to receive UroGen Pharma’s press releases and other company information?
Please visit the News section of our corporate website and choose the Email Alerts to be added to UroGen Pharma’s distribution list.
If I have questions regarding UroGen Pharma that have not been answered, whom should I contact?
For investor relations inquiries, you may submit inquiries by contacting Sara Blum Sherman, Head of Investor Relations, at 609-367-4975 or or sara.sherman@urogen.com.

Information Request

Material Selections
Address

Primary IR Contact

Sara Blum Sherman
Head of Investor Relations
Phone: 609-467-4975
E-mail: Sara.Sherman@urogen.com